[Expression of COX-2 in prostatic cancer and benign prostatic hyperplasia].
OBJECTIVE
To investigate the expression of COX-2 in and benign prostatic hyperplasia and prostate cancer and its clinical implications.


METHODS
Forty-two patients with and benign prostatic hyperplasia and 16 with prostate cancer were studied by immunohischemistry and western blot.


RESULTS
Immunohischemiscal study showed positive results in 15 of the 16 patients and 11 of the 42 patients. Western blot showed that the expression of COX-2 was higher in prostate cancer than in and benign prostatic hyperplasia tissues(P < 0.01).


CONCLUSIONS
Overexpression of COX-2 in prostate cancer may be related to the staging of prostate cancer.
Zang
T
T
Department of Urologic Surgery, Beijing Military General Hospital, Beijing 100700, China.
Sun
F
F
Li
Y
Y
D015153:Blotting, Western; D051546:Cyclooxygenase 2; D006801:Humans; D007150:Immunohistochemistry; D007527:Isoenzymes / Q000032:analysis* / Q000235:genetics; D008297:Male; D008565:Membrane Proteins; D008875:Middle Aged; D011451:Prostaglandin-Endoperoxide Synthases / Q000032:analysis* / Q000235:genetics; D011470:Prostatic Hyperplasia / Q000201:enzymology*; D011471:Prostatic Neoplasms / Q000201:enzymology*
D007527:Isoenzymes; D008565:Membrane Proteins; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases